Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Sponsor: Abramson Cancer Center at Penn Medicine

Sponsor score: 0

ClinicalTrials ID:NCT04691817

This clinical trial assesses the safety and efficacy of combining tocilizumab and atezolizumab in treating advanced non-squamous NSCLC. Eligible participants are adults with Stage IV or recurrent NSCLC, previously treated with a checkpoint inhibitor. Interventions include atezolizumab (1200mg infusion) and tocilizumab (6mg/kg or 4mg/kg infusion). Participants must have an ECOG PS of 0-2.

Patient Parameters

Program Overview

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Eligibility Criteria

Inclusion Criteria

  • Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • Prior exposure to at least 1 line of therapy
  • Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
  • ECOG PS 0-2

Exclusion Criteria

  • Presence of a driver mutation that is susceptible to targeted therapy
  • No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
  • Other active invasive malignancy requiring ongoing therapy
  • Evidence of progressing or untreated brain metastases
  • Evidence or history of leptomeningeal disease
  • Uncontrolled tumor related pain
  • History of an autoimmune disease or IPF

Locations

FACILITYZIPCITYSTATE
Abramson Cancer Center of the University of Pennsylvania19104PhiladelphiaPennsylvania

Get This Program In Your Inbox

You can sign up and apply your patients for this program.